ALINA (NCT03456076) was a global, randomized, open-label, phase III trial evaluating the clinical benefit of adjuvant alectinib compared to standard chemotherapy in patients with ALK-positive NSCLC in stage IB (tumors ≥ 4 cm), II, or IIIA (according to the 7th edition of the Cancer Staging Manual of the American Joint Committee on Cancer and the Union for International Cancer Control). This evidence concerns the gene ALK and non-small cell lung carcinoma.